A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03872947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Study identification
- NCT ID
- NCT03872947
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Toray Industries, Inc
- Industry
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- 5-FU Drug
- Bevacizumab Drug
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
- Imiquimod Cream Drug
- Irinotecan Drug
- Leucovorin Drug
- Nivolumab Drug
- PLD Drug
- Paclitaxel Drug
- Pembrolizumab Drug
- Ramucirumab Drug
- TRK-950 Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2019
- Primary completion
- May 31, 2026
- Completion
- May 31, 2026
- Last update posted
- Aug 2, 2025
2019 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| AOA-HOPE | Tucson | Arizona | 85711 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| HOAG Memorial Hospital Presbyterian | Newport | California | 92663 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center) | Eugene | Oregon | 97401 | — |
| Northwest Cancer Specialists | Portland | Oregon | 97227 | — |
| Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Downtown Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Virginia Cancer Specialists, PC | Leesburg | Virginia | 20176 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03872947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03872947 live on ClinicalTrials.gov.